CheckMate 9ER: Long-Term Follow-Up Data


Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

Related Videos
Video 11 - "Treating Patients With RCC Who Progress Following Adjuvant Therapy"
Related Content